To review the different pharmacological approaches to the cognitive, functional, and behavioural manifestations of Alzheimer disease (AD).
A D is the most common neurodegenerative disorder.
The World Alzheimer Report published in 2009 estimated that 35.6 million people will be living with dementia, worldwide, in 2010. 1 This figure will increase to 65.7 million by 2030 and to 115.4 million by 2050. The World Alzheimer Report published on Alzheimer's Day in September 2010 estimates the cost of dementia at $604 billion, globally, which is equivalent to 1% of the world's gross domestic product. 2 As are most aging industrialized countries, Canada is not spared by this disease. A report commissioned by the Alzheimer Society published in 2009 and entitled Rising Tide: The Impact of Dementia in Canada drew alarming conclusions. 3 According to this report, more than 480 000 Canadians (1.5% of Canada's population) were affected by dementia in 2008. This figure will more than double by 2038, reaching 1 125 200 people (2.8% of Canada's population). The cost of dementia in Canada will double every decade and increase from $15 billion in 2008 to $153 billion in 2038. The Rising Tide report 3 concluded by making 5 general recommendations, which include recognizing the importance of prevention and early intervention. This review will critically discuss the roles of vascular prevention, ChEIs, and memantine, an NMDA antagonist, in the pharmacological management of AD. The results of clinical trials studying potentially disease-modifying approaches in AD will also be discussed.
Mechanisms of Disease
A brief description of the mechanisms of disease involved in AD facilitates the understanding of current and future pharmacological interventions. Although the pathophysiology of AD is largely unknown, the amyloid cascade hypothesis is the main one proposed to explain the disease process. [4] [5] [6] According to this hypothesis, abnormal production or insufficient clearance of the Aβ protein is thought to result in extracellular amyloid plaque deposition, which in turn leads to secondary events, such as hyperphosphorylation of the protein tau and generation of NFTs, inflammation, excitotoxicity, and, eventually, cell death through activation of the apoptotic pathway. [7] [8] [9] These events cause deficits in neurotransmitters (especially ACh), which are thought to be responsible for the clinical manifestations of the disease. 10 The APP undergoes cleavage by 2 pathways (Figure 1 ). The sequential cleavage of APP by alpha-secretase and gamma-secretase leads to the formation of a soluble particle (p3 protein) that does not deposit abnormally. However, the sequential cleavage of APP by beta-secretase and gamma-secretase leads to the formation of insoluble Aβ that eventually deposits into amyloid plaques leading to the pathological process. Recent data suggest that soluble Aβ may be toxic before it actually deposits into plaques. 11, 12 An alternate hypothesis considers NFTs at the centre of the pathophysiological process. NFTs are produced by hyperphosphorylation of the protein tau, which is usually responsible of stabilizing the axonal cytosqueletton. [13] [14] [15] They lead to disruption in axonal transport and eventually to cell death.
In recent years, increased emphasis has been put on the vascular contribution to AD's pathophysiology. Most vascular risk factors are also risk factors for AD. 16 In the Nun Study, a longitudinal clinico-pathological study, the coexistence of ischemic lesions with plaques and tangles in the brains of participants increased the risk of clinical expression of dementia by a factor of 20. 17 A recent study shows that as people suffering from dementia get older, the neuropathological contribution of typical AD stigmata decreases, suggesting an incremental role for vascular contribution. [18] [19] [20] 
Approved Pharmacological Treatment

Vascular Prevention
The 2 vascular risk factors mostly studied with respect to cognitive outcomes are hypertension and dyslipidemia. Three RCTs have shown that optimal treatment of high blood pressure in people with or without cerebrovascular disease was associated with better cognitive outcomes. [21] [22] [23] HYVET evaluated the impact of treating hypertension on incidence of dementia in people aged 80 years and older. 24, 25 The treatment group in this study showed statistically significant benefits on cardiovascular and cerebrovascular outcomes. However, treatment of hypertension did not result in a reduction of dementia incidence. The results of HYVET were included in a metanalysis of all 4 primary prevention studies in hypertension evaluating incident dementia. The pooled relative risk calculated from this meta-analysis is borderline significant (RR 0.87; 95% CI 0.76 to 1.00, P = 0.04). The CCCDTD gave treatment of hypertension a grade B, level I recommendation as an option in primary prevention of cognitive decline. 26 Two major primary prevention RCTs evaluating the benefits of cholesterol-lowering medications showed statistically significant benefits on cardiovascular and cerebrovascular outcomes in treated people. 27, 28 However, there were no benefits on cognitive outcome measures used in these RCTs. These counterintuitive results can be explained, at least in part, by the relatively crude cognitive measures used and by the short duration of follow-up. A longitudinal observational study in a tertiary memory clinic showed that treatment of vascular risk factors is associated with a slower decline on cognitive measures in people with AD. 29
Abbreviations
Cholinesterase Inhibitors
There are 3 ChEIs available on the Canadian market: donepezil, rivastigmine, and galantamine. Use of these agents is based on studies showing that people with AD have deficits in ACh production leading to cortical cholinergic dysfunction. 30 Cholinesterase, which exists in 2 forms, BuChE and AChE, degrades ACh in the synaptic cleft. ChEIs act by inhibiting this action and optimize the levels of ACh available for postsynaptic stimulation. 31 ChEIs improve symptoms of AD, but they do not alter its natural clinical course. Hence they are considered symptomatic treatments for AD (Tables 1 and 2) .
Donepezil. Donepezil is a piperidine derivative that inhibits AChE. 32 A Cochrane review 33 evaluated the benefits of donepezil and included 24 trials and 5796 people with mild-to-severe AD. Pooled analyses showed statistically significant benefits on cognitive, global (clinician's or caregiver's impression of response to treatment), functional, and behavioural outcome measures ( Table 2 ). In general, both the doses of 5 and 10 mg daily were effective, with marginal incremental benefit at the higher dose. There were more dose-dependent side effects in donepezil-treated patients, the most common of which are nausea, vomiting, diarrhea, muscle cramps, dizziness, fatigue, and anorexia.
Rivastigmine. Rivastigmine is a carbamate derivative that reversibly inhibits both AChE and BuChE. 34 The clinical relevance of this dual inhibition is unclear. 35 A transdermal formulation of rivastigmine is currently available on the Canadian market, which aims at minimizing cholinergic side effects while allowing titration to the highest (and most effective) doses of the medication. 36, 37 A Cochrane review 38 including 9 trials and 4775 patients evaluated the benefits of rivastigmine in mild-to-moderate AD. Pooled analyses showed benefits on cognitive, global, and functional outcome measures (Table 2 ). There were no statistically significant benefits on behavioural outcomes. The benefits were observed mostly in people on the highest doses of the medication (6 to 12 mg daily). Side effects include nausea, vomiting, diarrhea, anorexia, headache, syncope, abdominal pain, and dizziness. The Investigation of transDermal Exelon in ALzheimer's disease (commonly referred to as IDEAL) study compared transdermal rivastigmine to oral rivastigmine. 37 The highest available transdermal dose (10 cm 2 ) was as effective as the oral maximal dose Galantamine. Galantamine is a tertiary alkaloid that reversibly inhibits AChE and allosterically binds to nicotinic receptors enhancing cholinergic transmission. 39 The clinical relevance of this unique additional property is unclear. A Cochrane review 40 including 10 clinical trials and 6805 patients with AD and mild cognitive impairment showed statistically significant treatment effects on cognitive, global, functional, and behavioural outcome measures ( Table 2 ). Unlike trials with other ChEIs, dose-response was inconsistent with galantamine, especially on measures of global rating. An RCT that studied patients with mixed AD with cerebrovascular disease and vascular dementia showed statistically significant treatment benefits at 24 weeks for doses of 16 to 24 mg daily on the Alzheimer's Disease Assessment Scale-Cognition (commonly referred to as ADAS-Cog), the CIBIC, the Disability Assessment for Dementia (commonly referred to as DAD) scale, and the Neuropsychiatric Inventory (commonly referred to as NPI). 41 Typical cholinergic side effects were more commonly reported in patients on galantamine, compared with placebo.
Memantine
Memantine is an NMDA noncompetitive glutamate receptor antagonist. 42 Its use in AD is based on studies showing that glutamate-related excitotoxicity is involved in the pathophysiology of the disease. 43 A Cochrane review 44 of memantine showed statistically significant treatment benefits at 24 weeks on measures of cognition, function, and global measures in pooled analyses of the 3 RCTs in moderate-to-severe AD. Analyses of the 3 unpublished trials in mild-to-moderate AD showed statistically significant treatment benefits on measures of cognition only. One study in moderate-to-severe AD showed that combining memantine to a stable dose of donepezil led to statistically significant additional benefits on measures of cognition (Severe Impairment Battery), function (Alzheimer's Disease Cooperative Study-Activities of Daily Living), and global assessment CIBIC. 45 Memantine is usually well tolerated. Dose-limiting side effects are rare and they consist of dizziness, headache, somnolence, and confusion. In Canada, memantine is approved for the treatment of moderate-to-severe AD.
Practical Issues in Current Pharmacological Management
Four clinical issues need to be considered when prescribing ChEIs and memantine for AD: treatment expectations, management of side effects, switching agents, and discontinuation of therapy.
Treatment Expectations. As mentioned previously, all available pharmacological treatments are symptomatic, and they do not alter progression of an otherwise neurodegenerative process. Treatment expectations need to be adjusted accordingly. It is challenging to translate the results of RCTs of several hundred patients to an individual patient with no placebo comparator. 46 In clinical practice, the individual patient, before treatment is started, serves as their own comparator, once treatment is instituted. Overall, in mild-to-moderate AD, patients tend to show improvement on cognitive measures that reach their peak at 6 months, and cross baseline at 9 to 12 months. On global measures, maximal benefit is usually observed at 3 months, and patients tend to cross baseline performance at 6 months. Patients do not typically show improvement on functional measures but rather a stabilization that lasts for an average of 6 months. Hence functions lost, such as managing one's finances or driving, should not be expected to significantly improve with treatment. Regarding behaviour, treatment with ChEIs usually prevents new neuropsychiatric symptoms in mild-to-moderate AD, and may help alleviate some of these symptoms in moderate-to-severe AD (such as depression, apathy, and anxiety). In moderate-to-severe AD, memantine Starting these agents at the lowest dose, and slowly titrating by no less than 4-week intervals to the minimally effective dose, helps to minimize these side effects. The transdermal formulation of rivastigmine is associated with considerably less gastrointestinal cholinergic side effects, but may be associated with skin intolerance in a minority of patients.
RCTs have excluded many subgroups of patients with common comorbidities. In the absence of clear guidelines regarding the treatment of patients with AD suffering from other serious medical comorbidities, we can only recommend prudence and an individualized approach based on clinicians' judgment.
Switching Agents. Even though ChEIs belong to the same general class, their individual pharmacological properties make switching a feasible option for intolerance or for lack of clinical response. 55 In the case of intolerance, we recommend clinicians wait for complete resolution of side effects of the initial agent before switching to the second agent, which can then be titrated according to the usual recommendations. In the case of lack of clinical response, which we define empirically as significant deterioration despite the use of a symptomatic medication at an effective dose for at least 6 months, switching to the second agent can be done overnight, with quicker titration (in 2-week intervals) until the minimal effective dose is reached. We do not recommend switching for loss of response after several years of treatment with a ChEI as this usually indicates natural progression to a more severe stage of the disease. In our experience, these people benefit from the addition of memantine rather than from switching to a second ChEI. Unfortunately, memantine is only reimbursed as monotherapy and in only one Canadian province.
Discontinuation of Therapy. Discontinuing therapy with ChEIs or memantine is both scientifically and emotionally challenging, and no clinical trial satisfyingly guides the clinicians confronted with this difficult decision. The CCCDTD has identified some indications for discontinuation of treatment in AD 50 (Table 3) . 
Emerging Treatments
Ever since Selkoe's proposal of the amyloid hypothesis 8,56 some 20 years ago, and as a result of our growing understanding of the multiple genes and proteins involved in the complex pathogenesis of AD, most pharmaceuticals in the development pipeline are created to act on individual protein targets in the hope of slowing or halting disease progression (and thus are potentially disease-modifying). In the discussion that follows, we attempt to place new drugs within this molecular framework and offer a road map to the mechanistic underpinnings of the categories of drugs in question. For more details, an authoritative review of the current state of phase II and III trials has recently been published. 57
Amyloid-Based Therapies
The amyloid cascade hypothesis 56 suggests that the accumulation of Aβ is the initial trigger to the AD pathophysiological process, and that all downstream events, potentially as, or possibly even more, devastating to neuronal integrity are simply consequential. Preventing the production, increasing or promoting the removal, and reducing the effective putative toxicity of Aβ are obvious goals.
Reducing Aβ Production. BACE1. Shifting of APP processing away from the amyloidogenic b-secretase (also called the b-site APP-cleaving enzyme 1 or BACE1) toward the nonamyloidogenic a-secretase pathway can be achieved by blocking BACE1. Inhibiting this enzyme directly may be problematic because it also cleaves numerous other substrates, including one involved in myelination, but an early candidate has completed a phase I trial. 58 Indirect modulation of BACE1 activity is possible through complex mechanisms involving the PPARg. 59 When stimulated, this factor reduces expression of BACE1 60 and leads to reductions in APP concentrations. 61 Because of its actions on glucose and lipids, PPARg is an important target in type II diabetes. Known PPARg ligands include the diabetic drugs rosiglitazone and pioglitazone. Although most RCTs of these drugs in AD are still ongoing, initial reports are not encouraging. 62, 63 g-Secretase. As depicted in Figure 1 , g-secretase cleaves both sAPPa and, completing the amyloidogenic pathway, sAPPb. It is also involved in numerous other processes, including the notch-signalling pathway critical to cell differentiation. 64 Numerous candidate drugs are in various trial phases. Despite promising phase II results, negative outcomes have led Eli Lilly to stop development of their inhibitor semagacestat 65 after completing 2 phase III trials. 66 Not all Abs are created equal. The amyloidogenic pathway can produce Ab peptides of sizes varying from 37 to 42 amino acids. The longer Ab42 species is thought to be critical to the aggregation process. 67 Certain chemicals, including some nonsteroidal antiinflammatroy drugs (commonly referred to as NSAIDS), collectively known as selective Ab42 lowering agents (commonly referred to as SALAs), can modulate g-secretase to shift Ab production toward the shorter form. 68 The first of these agents to clinical trials was tarenflurbil (R-flurbiprofen). Initial phase II results were encouraging, 69 but phase III RCTs failed to show beneficial effects. 70 a-Secretase. Shunting of APP toward nonamyloidogenesis could be achieved by stimulating a-secretase. Through a myriad of complex mechanisms, numerous agents appear to do just that, but their role in the treatment of AD is not established. 71 Candidates are in phase I or II studies, including exebryl-1, which potentially increases a-secretase activity, decreases b-secretase activity, and may even reduce tau aggregation. 72 Preventing Aβ Accumulation and Promoting Clearance. Regardless of any remaining controversy concerning which of the Ab species is most responsible for its ascribed neurotoxicity, 73 removal of all of its forms is a legitimate objective. Numerous agents able to prevent its selfassociation and downstream aggregation or even promote disaggregation are under investigation. 74 Preventing Aggregation. Alzhemed (tramiprosate or homotaurine) is a chemically produced agent naturally found in seaweed. As an early antiaggregant involved in human studies, it showed encouraging phase II trials. 75 Results from the subsequent phase III trial proved disappointing, perhaps as a consequence of an unusually high placebo response. 76 Post hoc analysis using volumetric magnetic resonance imaging showed possible slowing of Table 3 Indications for discontinuation of therapy in AD (adapted from Hogan et al 50 )
1. The patient and (or) their proxy decision maker decide to stop 2. Refusal to take the medication 3. Nonadherence to the medication 4. No response to therapy after a reasonable trial 5. Intolerable side effects 6. Comorbidities making continued use of the agent risky or futile 7. Progression to a stage of the disease where there is no significant benefit from continued therapy hippocampal atrophy. 77 The product has since been marketed as a memory loss-preventing neutraceutical (Vivimind) and generated much controversy. Caution is warranted as some data also suggest the drug may promote tau aggregation. 78 Ab aggregation, as well as numerous other pathological processes involved in AD, is promoted by the presence of certain metals, such as copper or zinc. 79 Small agents, such as quinolone analogues, are able to interfere with this interaction and produce positive effects in murine models 80 and in human phase II trials, 81, 82 but phase III trials have not yet been undertaken.
Other antiaggregants also showing promise that are currently in phase II trials include a polyphenol derived from green tea (epigallocatechin-3-gallate) 83 and an uncommon stereoisomer of the carbohydrate inositol (scyllo-inositol). 84 Promoting Clearance. Approaches to enhancing clearance include both passive and active immunization. Passive immunization includes monoclonal humanized antibodies (ending with the suffix -zumab). At least 6 candidates are presently under active phase II or III investigations, and results, although not spectacular, are promising. 57 Healthy donor-derived intravenous immunoglobulin can be used as a form of passive immunization. It contains naturally occurring anti-Ab antibodies, which are reduced in patients with AD. Although this agent is polyclonal and less specific, phase II trials have showed favourable outcomes, 85, 86 and phase III trials are ongoing. 87 As for active immunization, the phase I study involving AN172 (the first vaccine used in humans) had to be prematurely terminated because of the development of aseptic meningitis in 18 patients (of 300, or 6%). 88 This aggressive autoimmunity was attributed in part to the sensitization of cytotoxic T-cells. 89 One patient who died of the encephalitis showed significant clearing of Ab plaques. 90 Surviving patients who developed antibodies showed less functional decline, 91 but long-term postmortem analysis showed, despite documented reductions in Ab load, continued progression of other markers of neurodegeneration. 92 Numerous new vaccines are entering phase I trials and appear to reduce Ab load without producing encephalitis. 93 Although numerous stage II trials mentioned above have been promising, it should be noted that none of the completed phase III trials have yet to report positive results. There are surely several important factors that may explain these negative results, 94 but many are turning back and re-examining the hypothesis, including one of its creators. 95
Nonamyloid Strategies
The most salient neuropathological features present in brains of patients with AD are Ab plaques and, as the amyloid cascade hypothesis would have it, secondary hyperphosphorylated tau-based NFTs. Other downstream findings include inflammation, oxidative stress, and excitotoxicity (Figure 1) . Irrespective of the validity of the hypothesis or the actual sequence of events, any implicated process amenable to pharmacological modulation represents a viable target.
Tau-Targeted Therapies. Regardless of the inaugural event in AD, 96 because clinical severity is anatomically more closely related to tau pathology staging 97 than to Ab accumulations 98-100 it justifies targeting tau. Hyperphosphorylation of the tau leads to formation of NFTs.
A key phosphorylation enzyme (a kinase) in this process is GSK3, while protein phosphatase 2A is responsible for dephosphorylation. 101 Two well-known drugs, the mood stabilizers valproic acid (also an antiepileptic) and lithium, demonstrate some degree of GSK3 inhibition. For these drugs, analysis of available data and results from a phase II trial are not encouraging enough to justify proceeding to phase III studies, 102 possibly because brain concentrations high enough to inhibit GSK3 cannot be reached without untoward side effects. At least 5 other candidates have undergone encouraging phase II studies and are awaiting phase III conformation, 57 including vitamin B 3 (nicotinamide) 103 and methylene blue (Rember). 104 Other Downstream Processes to Target. More generalized targets, such as inflammation, oxidative stress (most often impacting mitochondria), and excitotoxicity, are also being actively explored, 57 but no convincing benefits have been demonstrated. Mitochondrial dysfunction is an emerging target. 105, 106 Mitochondrial stabilization was latrepirdine's (dimebon) main putative mode of action. Despite spectacular results from a phase II study in Russia, 107 a recent phase III study conducted in North America was negative.
Final Remarks
Pharmacological options are presently available for symptomatic treatment of AD. These treatments provide mild but sustained benefits. Before disease-modifying approaches become available, optimizing the use of the available treatment options is crucial. This is particularly important, because, although our growing understanding of the amyloid hypothesis and drug discovery targeting single steps in the hypothesized pathophysiological process have generated much enthusiasm, results of phase III trials have been relentlessly negative. The amyloid cascade hypothesis, the validity of our animal models, and even our ability to conduct clinical trials that will detect disease modification in patients with already diagnosed AD or even mild cognitive impairment (commonly referred to as MCI) are being questioned. 108 The amyloid cascade hypothesis remains, but more attention is directed at the role of other disease mechanisms. 109, 110 In Review
Résumé : Traitement pharmacologique de la maladie d'Alzheimer
Objectif : Examiner les différentes approches pharmacologiques des manifestations cognitives, fonctionnelles et comportementales de la maladie d'Alzheimer (MA).
Méthodes : Nous avons recherché la littérature pertinente la plus récente sur le traitement pharmacologique de la MA et en avons fait une analyse critique.
Résultats : L'approche pharmacologique actuelle du traitement de la MA se fonde sur la prévention vasculaire et la thérapie symptomatique au moyen d'inhibiteurs de la cholinestérase (IdCh) et de la mémantine, un antagoniste de l'acide N-méthyl-D-aspartate. Des essais cliniques d'une durée de 6 à 12 mois ont démontré les bénéfices statistiquement significatifs des IdCh et de la mémantine sur les mesures des résultats cognitifs, globaux, fonctionnels, et comportementaux. En général, ces bénéfices sont modestes. Cependant, ils sont proportionnels à la dose administrée et reproductibles dans toutes les études. Surtout, ces bénéfices sont symptomatiques car ils ne changent pas le cours de la maladie. Selon la Troisième conférence canadienne de consensus sur le diagnostic et le traitement de la démence, ces agents sont considérés comme étant des options de traitement standards de la MA. Nous discuterons des questions pratiques liées à la prise en charge pharmacologique actuelle, comme la détermination d'attentes réalistes, la prise en charge des effets secondaires, le changement d'IdCh, et la décision de cesser le traitement. Les résultats des essais cliniques qui étudient les approches ayant le potentiel de modifier la maladie dans la MA seront aussi examinés. Malheureusement, bien que les promesses et l'enthousiasme subsistent, aucun de ces agents n'a démontré de bénéfices constants, et ces agents ne sont pas disponibles dans la pratique clinique.
Conclusion :
Des options pharmacologiques sont présentement offertes pour le traitement symptomatique de la MA. Ces traitements procurent des bénéfices légers mais soutenus. Avant que des approches modifiant la maladie ne soient disponibles, l'optimisation de l'utilisation des options de traitement offertes est essentielle.
